AVBP Q1 2025 Earnings — ArriVent BioPharma, Inc. Common Stock Revenue & Financial Results | Market Cap Arena

AVBPArriVent BioPharma, Inc. Common Stock

$1B

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$67M

Net Income

-$64M

EPS (Diluted)

$-1.90

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$68M

Free Cash Flow

-$68M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$215M

Total Liabilities

$13M

Stockholders' Equity

$203M

Cash & Equivalents

$50M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$67M	-$21M	-223.0%
Net Income	-$64M	-$17M	-269.7%